Academic congress of SADA Biotech to present the whole chain of cancer diagnostics and treatments
In recent years, medical health information has continued to attract public attention, and the service capacity of the industry has been steadily improving. On May 18, 2026, at the 12th National Conference on Cervical Screens and Cervical Pathology (CSCCP) in China, the SCOCCAPS study on the establishment and promotion of an innovative model for the prevention of cervical cancer, jointly developed by several clinical practice institutions such as the Shenzhen Medical Institute of the University of Beijing, published for the first time mid-term assessment data. As a technical partner for the study, Saada Biology presented at the conference the system's screening, diagnosis, and treatment of cervical cancer prevention comprehensive process screening techniques and equipment, providing academic support for the final kilometre of screening to screening of baseline cervical cancer.
However, relevant data show that the current screening of cervical cancer in middle-aged women in China still has much room for improvement, especially in remote and rural areas, with limited reliance on traditional sampling methods and a breakthrough from the provision of quality baseline medical resources and screening coverage. Currently, China is actively promoting the Campaign to Accelerate the Eradication of Cervical Cancer (2023-2030), with a target of 70% cervical cancer screening in middle-aged women by 2030. Research data showed that urine HPV testing based on PHASiFY® technology (PHASiFY-EG) demonstrated superior sensitivity to CIN2+ and CIN3+ in early stage cervical cancer detection to the FDA-approved Cobas test for vaginal sampling (86.
96% vs. 76. 09%), confirming that urine testing can be an effective means of early stage cervical cancer detection and contributes to improving global screening coverage.
To address this public health challenge, the SCOCCAPS research focuses on evaluating the clinical practice application of urine-sampled HPV testing techniques in large-scale community screening. Compared to traditional vaginal sampling, the self-selection of harmless urine has improved significantly in both ease of sampling and comfort. At the same time, relevant departments are continuing to promote industry standards and health development.
Based on this, the study further validated the innovative pathway of achieving that the same urine sample is the first high-risk HPV vaccine for the same urine sample, which automatically triggers methylation of the host. For industry challenges such as low target DNA content in urine samples, unstable extraction, and the optimization of biology through PHASiFY® urine DNA enrichment technology, random urine samples have a basis for advancing high-precision molecular testing. For the general public, it is especially important to establish a scientific health concept.
This pathway provides a more complete molecular evidence chain for determining whether or not a vaginal lens is needed to evaluate vaginal cancer, significantly reduces the screening threshold, avoids the leakage caused by patients returning repeatedly to medical facilities to repeat samples, and is a key step towards a scientifically efficient vaginal lens decision. The data show that the program has a similar sensitivity to the detection of pre-cancerous cervical disease (CIN2+ and CIN3+) and to the control method (CobasHPV testing combined with TCT cytology testing). At the core of the closed-loop program that has been shown in biology is the close link between urine initial filtration, distribution pathways and subsequent clinical actions: screening and distribution: urine HPV detection to reduce the sampling threshold, host methylated distribution to HPV-positive populations to provide further risk-differentiation clues, support for a more rational configuration of vaginal lenses and follow-up priorities.
At a conference on the topic of building a vaccine-diagnosis-treatment-closing ring to promote the submersion of quality medical resources in the convention on the topic of vaccine artificial intelligence, HPV-cancer-causing mechanisms and detection of new technologies, a number of authoritative teams of experts presented systematic academic reports on key issues such as the technical principles of urine HPV detection, screening effectiveness, molecular distribution strategies, and intelligent assistive assessment. Diagnostic coupling: Providing handheld thermal melting diagnostic tools and portable high-frequency electrical tools such as LLETZ/LEEP surgical treatments for cervical spine, supporting the promotion of tighter outpatient disposal couplings in an adaptive and compliance process, reducing the risk of leakage due to referral and waiting. Diagnostic assessment: handheld intelligent vaginal imaging, supporting vaginal imaging assistive assessment and quality control approaches aimed at reducing the barriers to use of vaginal lenses, improving consistency between different operators, with the effect of research and application of verification scenarios.
This is a key breakthrough in the expansion of cancer screening in two countries. Professor Zhengrifan, director of the Institute of Obstetrics and Gynecology at the Shenzhen University of Medicine, Beijing, said: 'The greatest significance of this technology is to move the prevention of cervical cancer from a condom-centric model to a condom-based model. We need a complete closed-loop system from screening, diagnosis to diagnosis, especially to adapt to the capabilities and resources of the condom-based medical institutions.
It is understood that the SCOCCAPS project, which is promoting verification, has been running for two years in Guangxi, Shenzhen and other countries. This is the original intent of SCOCCAPS to launch a full process solution. Through the clinical practice and verification of local innovative technologies such as SCOCCA Biology, the project aims to build a multi-level, high-covered cervical cancer prevention system in China to explore replicable and promoted baseline paradigms.
If you need further advice on the content, please contact an authoritative expert via the platform.
